Newsfeeds - Spark Newswire

Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Read More

1 minute read

Intersect ENT Q3 EPS $(0.48) Down From $(0.34) YoY, Sales $24.40M Up From $22.72M YoY

By Benzinga Newsdesk

Today, 3:40 PM

Intersect ENT (NASDAQ:XENT) reported quarterly losses of $(0.48) per share. This is a 41.18 percent decrease over losses of $(0.34) per share from the same period last year. The company reported $24.40 million in sales

Read More

2 minute read

Global
News

Intersect ENT Announces First Implants Of PROPEL Contour In Patients With Chronic Rhinosinusitis Following Frontal Sinus Surgery In Europe

By Benzinga Newsdesk

Today, 3:40 PM

Intersect ENT®, Inc. (NASDAQ:XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden

Read More

12 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For August 12, 2021

By Benzinga Insights

Today, 3:40 PM

Read More

1 minute read

SVB Leerink Downgrades Intersect ENT to Market Perform, Announces $28.25 Price Target

By Benzinga Newsdesk

Today, 3:40 PM

SVB Leerink analyst Richard Newitter downgrades Intersect ENT (NASDAQ:XENT) from Outperform to Market Perform and announces $28.25 price target.

Read More

5 minute read

The Daily Biotech Pulse: FDA Rejects FibroGen’s Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering

By Shanthi Rexaline

Today, 3:40 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)

Read More

9 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For August 10, 2021

By Benzinga Insights

Today, 3:40 PM

Read More

6 minute read

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck’s Keytruda On Track For More Label Expansions, Eliem Debuts

By Shanthi Rexaline

Today, 3:40 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9)

Read More

1 minute read

BTIG Downgrades Intersect ENT to Neutral

By Benzinga Newsdesk

Today, 3:40 PM

BTIG analyst Ryan Zimmerman downgrades Intersect ENT (NASDAQ:XENT) from Buy to Neutral.

Read More

1 minute read

Canaccord Genuity Downgrades Intersect ENT to Hold, Lowers Price Target to $28.25

By Benzinga Newsdesk

Today, 3:40 PM

Canaccord Genuity analyst Kyle Rose downgrades Intersect ENT (NASDAQ:XENT) from Buy to Hold and lowers the price target from $29 to $28.25.

Read More

16 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For August 9, 2021

By Benzinga Insights

Today, 3:40 PM

Upgrades